Regeneron reported lasting improvements in liver fat and injury markers after one dose, with no trial dropouts or reported nausea or vomiting. The early results are promising, but long-term safety and liver tissue results are still being studied.
The findings suggest CIDEBsiRNA could help people with this liver disease. The lasting changes and lack of reported nausea or vomiting support that reading. More testing is still needed to check long-term safety and liver tissue results.
Follow Regeneron Pharmaceuticals (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for REGN